165 related articles for article (PubMed ID: 24764582)
21. Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.
Flietner E; Wen Z; Rajagopalan A; Jung O; Watkins L; Wiesner J; You X; Zhou Y; Sun Y; Kingstad-Bakke B; Callander NS; Rapraeger A; Suresh M; Asimakopoulos F; Zhang J
Sci Rep; 2022 Jun; 12(1):10616. PubMed ID: 35739276
[TBL] [Abstract][Full Text] [Related]
22. The development and function of human monocyte-derived dendritic cells regulated by metabolic reprogramming.
Zhao Y; Gao C; Liu L; Wang L; Song Z
J Leukoc Biol; 2023 Sep; 114(3):212-222. PubMed ID: 37232942
[TBL] [Abstract][Full Text] [Related]
23. Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration.
Degan S; May BL; Jin YJ; Hammoda MB; Sun H; Zhang G; Wang Y; Erdmann D; Warren W; Zhang JY
Front Oncol; 2022; 12():782877. PubMed ID: 35847840
[TBL] [Abstract][Full Text] [Related]
24. MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression.
Rodriguez BL; Gibbons DL
Cell Rep Med; 2022 Jan; 3(1):100506. PubMed ID: 35106515
[TBL] [Abstract][Full Text] [Related]
25. To Inhibit or Not to Inhibit MEK With BRAF Inhibitors: Is That the Question?
Sullivan RJ
J Clin Oncol; 2023 Oct; 41(29):4613-4615. PubMed ID: 37590898
[No Abstract] [Full Text] [Related]
26. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
27. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
28. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Atefi M; Avramis E; Lassen A; Wong DJ; Robert L; Foulad D; Cerniglia M; Titz B; Chodon T; Graeber TG; Comin-Anduix B; Ribas A
Clin Cancer Res; 2014 Jul; 20(13):3446-57. PubMed ID: 24812408
[TBL] [Abstract][Full Text] [Related]
29. Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.
Cooper ZA; Reuben A; Austin-Breneman J; Wargo JA
Clin Cancer Res; 2015 Jul; 21(14):3102-4. PubMed ID: 26025561
[TBL] [Abstract][Full Text] [Related]
30. The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.
Vella LJ; Andrews MC; Pasam A; Woods K; Behren A; Cebon JS
Oncoimmunology; 2014; 3(7):e946367. PubMed ID: 25610732
[TBL] [Abstract][Full Text] [Related]
31. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
Ebert PJR; Cheung J; Yang Y; McNamara E; Hong R; Moskalenko M; Gould SE; Maecker H; Irving BA; Kim JM; Belvin M; Mellman I
Immunity; 2016 Mar; 44(3):609-621. PubMed ID: 26944201
[TBL] [Abstract][Full Text] [Related]
32. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
33. Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.
Zdanov S; Mandapathil M; Abu Eid R; Adamson-Fadeyi S; Wilson W; Qian J; Carnie A; Tarasova N; Mkrtichyan M; Berzofsky JA; Whiteside TL; Khleif SN
Cancer Immunol Res; 2016 Apr; 4(4):354-65. PubMed ID: 26880715
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
35. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
37. Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.
Allegrezza MJ; Rutkowski MR; Stephen TL; Svoronos N; Perales-Puchalt A; Nguyen JM; Payne KK; Singhal S; Eruslanov EB; Tchou J; Conejo-Garcia JR
Cancer Res; 2016 Nov; 76(21):6253-6265. PubMed ID: 27803104
[TBL] [Abstract][Full Text] [Related]
38. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
Kim T; Amaria RN; Spencer C; Reuben A; Cooper ZA; Wargo JA
Cancer Biol Med; 2014 Dec; 11(4):237-46. PubMed ID: 25610709
[TBL] [Abstract][Full Text] [Related]
39. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS; Soria JC; Kowanetz M; Fine GD; Hamid O; Gordon MS; Sosman JA; McDermott DF; Powderly JD; Gettinger SN; Kohrt HE; Horn L; Lawrence DP; Rost S; Leabman M; Xiao Y; Mokatrin A; Koeppen H; Hegde PS; Mellman I; Chen DS; Hodi FS
Nature; 2014 Nov; 515(7528):563-7. PubMed ID: 25428504
[TBL] [Abstract][Full Text] [Related]
40. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
